Literature DB >> 9588888

Coronary arteriosclerosis after T-cell-mediated injury in transplanted mouse hearts: role of interferon-gamma.

H Nagano1, P Libby, M K Taylor, S Hasegawa, J L Stinn, G Becker, N L Tilney, R N Mitchell.   

Abstract

This study evaluated the contribution of acute parenchymal rejection and interferon (IFN)-gamma to the development of graft arterial disease (GAD) in totally allogeneic murine cardiac transplants. BALB/c (H-2d) hearts were transplanted into wild-type C57BL/6 (B6, H-2b) or B6 IFN-gamma-deficient (GKO) recipient mice. Assessing the role of acute parenchymal rejection in the GAD process involved two different immunosuppression protocols using anti-CD4 and -CD8 monoclonal antibodies (MAbs): virtually complete long-term immunosuppression (denoted as complete immunosuppression) was achieved by administering both MAbs 6, 3, and 1 day before transplantation and weekly thereafter; in contradistinction, a single, early, transient episode of rejection (transient rejection) was attained by administering MAbs beginning 4 days after transplant and then at weekly intervals. The extent and duration of T cell depletion under these two regimens were evaluated using flow cytometric analysis of peripheral blood lymphocytes. After a single injection of MAbs, peripheral blood CD4+ and CD8+ T cell depletion was approximately 98% at 1 week and approximately 88% at 2 weeks. After three injections (analogous to days 6, 3, and 1 before transplant), peripheral blood CD4+ and CD8+ T cell depletion was >98% at 2 weeks and approximately 87% at 4 weeks. Functioning cardiac allografts were removed at 8 and 12 weeks after transplant and analyzed by hematoxylin and eosin, elastic tissue, and immunohistochemical stains, and the severity of parenchymal rejection versus GAD was scored. With complete immunosuppression (antibody before and after transplant), BALB/c allografts showed little parenchymal rejection or GAD, suggesting that persistent depletion of T cells blocked subsequent development of GAD. However, even a single transient acute rejection episode allowed the subsequent development of GAD accompanied by augmented major histocompatibility complex (MHC) class II, VCAM-1, and ICAM-1 expression at 12 weeks; these allografts showed no residual CD4+ or CD8+ T cells. In comparison, allografts undergoing transient rejection in GKO recipients did not develop GAD, despite persistent macrophage and natural killer cell (NK) infiltrates comparable to those seen in wild-type recipients. Moreover, the arterioles of hearts transplanted into GKO recipients showed no or minimal increases in MHC class II, ICAM-1, and VCAM-1 relative to baseline expression. In conclusion, a single episode of allogeneic injury mediated by T cells suffices to evoke subsequent graft arteriosclerosis, even in the absence of additional T-cell-mediated injury, and the process appears to depend on IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9588888      PMCID: PMC1858591     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  47 in total

1.  Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1).

Authors:  M L Dustin; R Rothlein; A K Bhan; C A Dinarello; T A Springer
Journal:  J Immunol       Date:  1986-07-01       Impact factor: 5.422

2.  Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection.

Authors:  R J Corry; H J Winn; P S Russell
Journal:  Transplantation       Date:  1973-10       Impact factor: 4.939

3.  Reduction in cellular and vascular rejection by blocking leukocyte adhesion molecule receptors.

Authors:  M Sadahiro; T O McDonald; M D Allen
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

4.  Treatment with anti-vascular cell adhesion molecule 1 monoclonal antibody induces long-term murine cardiac allograft acceptance.

Authors:  C G Orosz; R G Ohye; R P Pelletier; A M Van Buskirk; E Huang; C Morgan; P W Kincade; R M Ferguson
Journal:  Transplantation       Date:  1993-08       Impact factor: 4.939

5.  Importance of endothelial VCAM-1 for inflammatory leukocytic infiltration in vivo.

Authors:  R P Pelletier; R G Ohye; A Vanbuskirk; D D Sedmak; P Kincade; R M Ferguson; C G Orosz
Journal:  J Immunol       Date:  1992-10-01       Impact factor: 5.422

6.  Regulation of MHC class I and beta 2-microglobulin gene expression in human neuronal cells. Factor binding to conserved cis-acting regulatory sequences correlates with expression of the genes.

Authors:  P D Drew; M Lonergan; M E Goldstein; L A Lampson; K Ozato; D E McFarlin
Journal:  J Immunol       Date:  1993-04-15       Impact factor: 5.422

7.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

Authors:  D K Dalton; S Pitts-Meek; S Keshav; I S Figari; A Bradley; T A Stewart
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro.

Authors:  T Collins; L A Lapierre; W Fiers; J L Strominger; J S Pober
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

9.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.

Authors:  C F Nathan; H W Murray; M E Wiebe; B Y Rubin
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

10.  Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by gamma interferon.

Authors:  M J Skoskiewicz; R B Colvin; E E Schneeberger; P S Russell
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307

View more
  18 in total

Review 1.  Vascular smooth muscle cell apoptosis in atherosclerosis.

Authors:  J J Boyle
Journal:  Int J Exp Pathol       Date:  1999-08       Impact factor: 1.925

Review 2.  Stem cell origins of intimal cells in graft arterial disease.

Authors:  Koichi Shimizu; Richard N Mitchell
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

Review 3.  The link between IFN-gamma and allograft arteriopathy: is the answer NO?

Authors:  Richard N Mitchell; Andrew H Lichtman
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

4.  Interleukin-10 (IL-10) augments allograft arterial disease: paradoxical effects of IL-10 in vivo.

Authors:  Y Furukawa; G Becker; J L Stinn; K Shimizu; P Libby; R N Mitchell
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

5.  Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy.

Authors:  R S Lee; K Yamada; S L Houser; K L Womer; M E Maloney; H S Rose; M H Sayegh; J C Madsen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

6.  AIP1 prevents graft arteriosclerosis by inhibiting interferon-γ-dependent smooth muscle cell proliferation and intimal expansion.

Authors:  Luyang Yu; Lingfeng Qin; Haifeng Zhang; Yun He; Hong Chen; Jordan S Pober; George Tellides; Wang Min
Journal:  Circ Res       Date:  2011-06-23       Impact factor: 17.367

Review 7.  AIP1 in graft arteriosclerosis.

Authors:  Wang Min; Jordan S Pober
Journal:  Trends Cardiovasc Med       Date:  2011-11       Impact factor: 6.677

8.  Mouse models for graft arteriosclerosis.

Authors:  Lingfeng Qin; Luyang Yu; Wang Min
Journal:  J Vis Exp       Date:  2013-05-14       Impact factor: 1.355

9.  T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase.

Authors:  Kian Peng Koh; Yinong Wang; Tai Yi; Stephen L Shiao; Marc I Lorber; William C Sessa; George Tellides; Jordan S Pober
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

10.  Anti-interleukin-12/23p40 antibody attenuates chronic rejection of cardiac allografts partly via inhibition γδT cells.

Authors:  S Wang; X Xu; A Xie; J Li; P Ye; Z Liu; J Wu; L Rui; J Xia
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.